Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:21321187rdf:typepubmed:Citationlld:pubmed
pubmed-article:21321187lifeskim:mentionsumls-concept:C0026844lld:lifeskim
pubmed-article:21321187lifeskim:mentionsumls-concept:C1135918lld:lifeskim
pubmed-article:21321187lifeskim:mentionsumls-concept:C0034338lld:lifeskim
pubmed-article:21321187lifeskim:mentionsumls-concept:C0033414lld:lifeskim
pubmed-article:21321187lifeskim:mentionsumls-concept:C0812228lld:lifeskim
pubmed-article:21321187lifeskim:mentionsumls-concept:C0392747lld:lifeskim
pubmed-article:21321187lifeskim:mentionsumls-concept:C1554963lld:lifeskim
pubmed-article:21321187lifeskim:mentionsumls-concept:C1514485lld:lifeskim
pubmed-article:21321187pubmed:issue5lld:pubmed
pubmed-article:21321187pubmed:dateCreated2011-5-2lld:pubmed
pubmed-article:21321187pubmed:abstractTextMethylglyoxal (MG), a reactive dicarbonyl molecule, can modify protein to form advanced glycation endproducts. Increased MG level has been implicated in proliferative vascular diseases, but the underlying mechanisms are not clear yet. The serine/threonine kinase, Akt, regulates multiple signaling pathways that control cell proliferation. Using mass spectrometric analysis, we have detected the modification of Akt1 by MG at Cys(77). This structural modification increased Akt1 phosphorylation at Ser(473) and Thr(308). Akt1 phosphorylation and activity were also increased by MG treatment (<50 ?M) in cultured vascular smooth muscle cells (VSMCs). MG treatment of VSMCs led to increased DNA synthesis (EC(50)=5.8 ?M), cell proliferation, phosphorylation of p21 and glycogen synthase kinase-3?/? (GSK-3?/?), and increased cyclin-dependent kinase 2 (CDK2) activity. These effects of MG were significantly inhibited by silencing Akt1 or by an Akt inhibitor. Overexpression of Akt1 Cys(77)Ser mutant in HEK-293 cells increased cell proliferation and DNA synthesis, concurrent with an increase in Akt1 activity, which could not be further augmented by MG treatment. It is concluded that MG-induced VSMC proliferation is mediated by the activation of Akt1 via the modification of Akt1 at Cys(77).lld:pubmed
pubmed-article:21321187pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21321187pubmed:languageenglld:pubmed
pubmed-article:21321187pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21321187pubmed:citationSubsetIMlld:pubmed
pubmed-article:21321187pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21321187pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21321187pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21321187pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21321187pubmed:statusMEDLINElld:pubmed
pubmed-article:21321187pubmed:monthMaylld:pubmed
pubmed-article:21321187pubmed:issn1530-6860lld:pubmed
pubmed-article:21321187pubmed:authorpubmed-author:WangRuiRlld:pubmed
pubmed-article:21321187pubmed:authorpubmed-author:WuLingyunLlld:pubmed
pubmed-article:21321187pubmed:authorpubmed-author:RossAndrew...lld:pubmed
pubmed-article:21321187pubmed:authorpubmed-author:OlsonDouglas...lld:pubmed
pubmed-article:21321187pubmed:authorpubmed-author:MousseauDarre...lld:pubmed
pubmed-article:21321187pubmed:authorpubmed-author:ChangTuanjieTlld:pubmed
pubmed-article:21321187pubmed:issnTypeElectroniclld:pubmed
pubmed-article:21321187pubmed:volume25lld:pubmed
pubmed-article:21321187pubmed:ownerNLMlld:pubmed
pubmed-article:21321187pubmed:authorsCompleteYlld:pubmed
pubmed-article:21321187pubmed:pagination1746-57lld:pubmed
pubmed-article:21321187pubmed:meshHeadingpubmed-meshheading:21321187...lld:pubmed
pubmed-article:21321187pubmed:meshHeadingpubmed-meshheading:21321187...lld:pubmed
pubmed-article:21321187pubmed:meshHeadingpubmed-meshheading:21321187...lld:pubmed
pubmed-article:21321187pubmed:meshHeadingpubmed-meshheading:21321187...lld:pubmed
pubmed-article:21321187pubmed:meshHeadingpubmed-meshheading:21321187...lld:pubmed
pubmed-article:21321187pubmed:meshHeadingpubmed-meshheading:21321187...lld:pubmed
pubmed-article:21321187pubmed:meshHeadingpubmed-meshheading:21321187...lld:pubmed
pubmed-article:21321187pubmed:meshHeadingpubmed-meshheading:21321187...lld:pubmed
pubmed-article:21321187pubmed:meshHeadingpubmed-meshheading:21321187...lld:pubmed
pubmed-article:21321187pubmed:meshHeadingpubmed-meshheading:21321187...lld:pubmed
pubmed-article:21321187pubmed:meshHeadingpubmed-meshheading:21321187...lld:pubmed
pubmed-article:21321187pubmed:meshHeadingpubmed-meshheading:21321187...lld:pubmed
pubmed-article:21321187pubmed:meshHeadingpubmed-meshheading:21321187...lld:pubmed
pubmed-article:21321187pubmed:meshHeadingpubmed-meshheading:21321187...lld:pubmed
pubmed-article:21321187pubmed:meshHeadingpubmed-meshheading:21321187...lld:pubmed
pubmed-article:21321187pubmed:meshHeadingpubmed-meshheading:21321187...lld:pubmed
pubmed-article:21321187pubmed:year2011lld:pubmed
pubmed-article:21321187pubmed:articleTitleModification of Akt1 by methylglyoxal promotes the proliferation of vascular smooth muscle cells.lld:pubmed
pubmed-article:21321187pubmed:affiliationDepartment of Pharmacology, College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.lld:pubmed
pubmed-article:21321187pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:21321187pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed